about
Willingness to pay for a new drug delivery in Parkinson patientsContinuous drug delivery in Parkinson's disease.Eryptosis as a marker of Parkinson's diseaseSafety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents.Drug Safety Analysis in a Real-Life Cohort of Parkinson's Disease Patients with Polypharmacy.Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.Allergic contact dermatitis caused by rotigotine in a transdermal therapeutic system.
P2860
Q30428083-37C46ED6-24E0-4C4B-9B29-8A8276A90803Q34390800-D734226A-4CB1-4BEF-A630-331B461DC70DQ34585744-0898B076-19FF-458D-9247-7347F976C059Q38223072-5237A56D-6D3F-467D-B27D-08418235CA3FQ43248920-A974C6B1-0CF6-4DE9-BB33-5FB0851D442CQ47838959-3E4CA4A0-AA9F-40AB-B3C7-5A6EA547E831Q48333289-8B48CD3C-DE77-481D-91DD-9556CC878E8AQ51262929-81E4B077-562A-4223-B273-2673DDA0B59E
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Drug safety evaluation of rotigotine.
@en
Drug safety evaluation of rotigotine.
@nl
type
label
Drug safety evaluation of rotigotine.
@en
Drug safety evaluation of rotigotine.
@nl
prefLabel
Drug safety evaluation of rotigotine.
@en
Drug safety evaluation of rotigotine.
@nl
P2860
P1476
Drug safety evaluation of rotigotine.
@en
P2093
Fabienne Stephanie Sprenger
P2860
P304
P356
10.1517/14740338.2012.678830
P407
P577
2012-04-03T00:00:00Z